Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are routinely used
to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of …

Background Combined inhibition of vascular, platelet-derived, and epidermal growth factor
receptor (EGFR) pathways may overcome refractoriness to single agents in platinum …

Clinical experience with the EGFR-TKI gefitinib in Asian patients with NSCLC will be
reviewed, both in patients who have previously failed chemotherapy and in the first-line …

Current standard therapy for advanced or metastatic non-small cell lung cancer (NSCLC)
includes chemotherapy, which is often associated with limited efficacy and toxicity. Thus …

Purpose There is as yet no optimal treatment regimen for patients with epidermal growth
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …

Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …

Background Erlotinib is registered for treatment of all patients with advanced non-small-cell
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …

Introduction• Literature review‐Molecular biology of EGFR mutations‐Clinical characteristics
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …

Molecular targeted therapies, such as the epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs), provide a different mechanism of action from chemotherapy and can …

Background: Improvements in first-line therapy of advanced non-small-cell lung cancer
(NSCLC) have increased the need for effective second-line treatment options. In a Phase II …